Skip to main content

Corinne Mary Linardic

Associate Professor of Pediatrics
Pediatrics, Hematology-Oncology
Box 102382, DUMC, Durham, NC 27710
LSRC Bldg Rm B361F, Research Drive, Durham, NC 27710

Overview


Pediatric Sarcomas: Sarcomas are among the most difficult-to-treat cancers in pediatric oncology, with metastatic forms having the highest mortality. We have established genetically defined human cell-based models and genetically engineered murine models for the pediatric skeletal muscle cancer known as rhabdomyosarcoma. Using these models, we can study the causative role of certain genetic changes (e.g. chromosomal translocations and oncogenic RAS) in rhabdomyosarcoma formation and treatment resistance. Specific goals of this research program include the identification of signaling pathways corrupted in rhabdomyosarcoma, with focus on the PAX3::FOXO1 mutation and its downstream effectors and oncogenic RAS, and identification of new therapeutic targets for treatment of this childhood cancer.

Current Duke Appointments & Affiliations


Associate Professor of Pediatrics · 2012 - Present Pediatrics, Hematology-Oncology, Pediatrics
Associate Professor of Pharmacology and Cancer Biology · 2012 - Present Pharmacology & Cancer Biology, Basic Science Departments
Associate Professor of Cell Biology · 2022 - Present Cell Biology, Basic Science Departments
Member of the Duke Cancer Institute · 1999 - Present Duke Cancer Institute, Institutes and Centers

Recent News Items


Published April 29, 2025
Daily Takeaways From the AACR Annual Meeting 2025: Tuesday, April 29

View All News Items

Recent Scholarly Works


Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

Journal article Br J Cancer · June 13, 2026 The third in a series of Paediatric Therapeutic Development Workshops focused on rhabdomyosarcoma. Rhabdomyosarcoma is the most common soft tissue sarcoma in children, with 90% survival for those with the lowest risk disease, but just 20-30% in children wi ... Full text Link to item Cite

Fusion-positive rhabdomyosarcoma oncofusions share a common interactome.

Journal article Nat Commun · May 28, 2026 Fusion-positive rhabdomyosarcoma (FP-RMS) arises from at least seven distinct oncofusions sharing a common PAX3/7 N-terminal DNA-binding domain fused to divergent C-terminal partners. How different oncofusions produce the same cancer was unknown. Here we s ... Full text Link to item Cite

Abstract 1155: High-throughput screening identifies synergistic drug interactions between CDK8/19 and DHFR inhibitors in rhabdomyosarcoma

Conference Cancer Research · April 3, 2026 AbstractRhabdomyosarcoma (RMS) is an aggressive pediatric soft-tissue sarcoma marked by substantial treatment-related morbidity and poor outcomes, particularly in metastatic or recurrent disease. Although ... Full text Cite
View All Scholarly Works

Recent Grants


Cell and Molecular Biology Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institute of General Medical Sciences · 2026 - 2031

Identification and targeting of essential regions of driver fusion oncoproteins in rhabdomyosarcoma

ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2025 - 2030

Pharmacological Sciences Training Program

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030

View All Grants

Education


Duke University · 1995 M.D.
Duke University · 1993 Ph.D.